These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
313 related items for PubMed ID: 32199895
1. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, Li S, de Souza MP, Murrell DF, Marinkovich MP, Tang JY. J Am Acad Dermatol; 2021 Nov; 85(5):1161-1167. PubMed ID: 32199895 [Abstract] [Full Text] [Related]
2. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Tang JY, Marinkovich MP, Lucas E, Gorell E, Chiou A, Lu Y, Gillon J, Patel D, Rudin D. Orphanet J Rare Dis; 2021 Apr 13; 16(1):175. PubMed ID: 33849616 [Abstract] [Full Text] [Related]
3. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey. Fulchand S, Harris N, Li S, Barriga M, Gorell E, De Souza M, Murrell D, Marinkovich MP, Krishna Yenamandra V, Tang JY. Pediatr Dermatol; 2021 Sep 13; 38(5):1198-1201. PubMed ID: 34515355 [Abstract] [Full Text] [Related]
4. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex. So JY, Fulchand S, Wong CY, Li S, Nazaroff J, Gorell ES, de Souza MP, Murrell DF, Teng JM, Chiou AS, Tang JY. Orphanet J Rare Dis; 2022 Jul 15; 17(1):270. PubMed ID: 35841105 [Abstract] [Full Text] [Related]
5. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. Venugopal SS, Yan W, Frew JW, Cohn HI, Rhodes LM, Tran K, Melbourne W, Nelson JA, Sturm M, Fogarty J, Marinkovich MP, Igawa S, Ishida-Yamamoto A, Murrell DF. J Am Acad Dermatol; 2013 Dec 15; 69(6):898-908.e7. PubMed ID: 24075228 [Abstract] [Full Text] [Related]
7. Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study. Mellerio JE, Pillay EI, Ledwaba-Chapman L, Bisquera A, Robertson SJ, Papanikolaou M, McGrath JA, Wang Y, Martinez AE, Jeffs E. Orphanet J Rare Dis; 2023 Aug 09; 18(1):235. PubMed ID: 37559055 [Abstract] [Full Text] [Related]
8. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. So JY, Nazaroff J, Iwummadu CV, Harris N, Gorell ES, Fulchand S, Bailey I, McCarthy D, Siprashvili Z, Marinkovich MP, Tang JY, Chiou AS. Orphanet J Rare Dis; 2022 Oct 17; 17(1):377. PubMed ID: 36253825 [Abstract] [Full Text] [Related]
9. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa. Paller AS, Pope E, Rudin D, Malyala A, Ramsdell D, Johnson R, Landy H, Murrell DF, DEB Investigators. Orphanet J Rare Dis; 2022 Aug 13; 17(1):314. PubMed ID: 35964087 [Abstract] [Full Text] [Related]
10. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America. Feinstein JA, Jambal P, Peoples K, Lucky AW, Khuu P, Tang JY, Lara-Corrales I, Pope E, Wiss K, Hook KP, Levin LE, Morel KD, Paller AS, McCuaig CC, Powell J, Eichenfield LF, Price H, Levy ML, Schachner LA, Browning JC, Bayliss S, Jahnke M, Shwayder T, Glick SA, Bruckner AL. JAMA Dermatol; 2019 Feb 01; 155(2):196-203. PubMed ID: 30586139 [Abstract] [Full Text] [Related]
16. Electrochemotherapy, a local treatment for squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. Bartolo J, Farricha V, Carvalhal S, Moura C, Abecasis N. Dermatol Ther; 2020 Nov 11; 33(6):e14093. PubMed ID: 32720460 [Abstract] [Full Text] [Related]
17. Functional genotype-phenotype associations in recessive dystrophic epidermolysis bullosa. So JY, Nazaroff J, Yenamandra VK, Gorell ES, Harris N, Fulchand S, Eid E, Dolorito JA, Marinkovich MP, Tang JY. J Am Acad Dermatol; 2024 Sep 11; 91(3):448-456. PubMed ID: 38735484 [Abstract] [Full Text] [Related]
18. ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa. Dieter K, Niebergall-Roth E, Daniele C, Fluhr S, Frank NY, Ganss C, Kiritsi D, McGrath JA, Tolar J, Frank MH, Kluth MA. Cytotherapy; 2023 Jul 11; 25(7):782-788. PubMed ID: 36868990 [Abstract] [Full Text] [Related]
19. Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa. Popp C, Miller W, Eide C, Tolar J, McGrath JA, Ebens CL. J Invest Dermatol; 2024 Sep 11; 144(9):1943-1953. PubMed ID: 38613531 [Abstract] [Full Text] [Related]
20. Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa. Solis DC, Gorell ES, Teng C, Barriga M, Nazaroff J, Li S, Subica A, Lu Y, Marinkovich MP, Tang JY. Pediatr Dermatol; 2021 May 11; 38(3):704-706. PubMed ID: 33749033 [Abstract] [Full Text] [Related] Page: [Next] [New Search]